Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

PRX019

Other · developed by Prothena Biosciences

Phase 1 Most advanced trial (none active)
PRTA Developer
1 Registered trials

What is PRX019?

PRX019 is an investigational drug studied in Healthy Participants Study.

At a glance

Drug type
Other
Developer
Prothena Biosciences Ltd. (PRTA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06699680 Phase 1 Healthy Participants Study Completed PRTA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy Participants Study

More from Prothena Biosciences

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PRTA page.

Follow PRTA, the company behind PRX019

See PRTA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PRTA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.